Evidence map›Paper›PMID 27479095›Full record

ArticlePloS one2016

Generation and Characterization of an IgG4 Monomeric Fc Platform.

Lu Shan, Magali Colazet, Kim L Rosenthal, Xiang-Qing Yu, Jared S Bee, Andrew Ferguson, Melissa M Damschroder, Herren Wu, William F Dall'Acqua, Ping Tsui and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Receptor usage of Syncytin-1: ASCT2, but not ASCT1, is a functional receptor and effector of cell fusion in the human placenta.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Lu ShanAntibody Discovery and Protein Engineering, MedImmune, Gaithersburg, Maryland, United States of America.
Magali ColazetAntibody Discovery and Protein Engineering, MedImmune, Gaithersburg, Maryland, United States of America.
Kim L RosenthalAntibody Discovery and Protein Engineering, MedImmune, Gaithersburg, Maryland, United States of America.
Xiang-Qing YuClinical Pharmacology and Drug Metabolism and Pharmacokinetics, MedImmune, Gaithersburg, Maryland, United States of America.
Jared S BeeAnalytical Biotechnology, MedImmune, Gaithersburg, Maryland, United States of America.
Andrew FergusonDiscovery Sciences, Structure and Biophysics, AstraZeneca Pharmaceuticals, Waltham, Massachusetts, United States of America.
Melissa M DamschroderAntibody Discovery and Protein Engineering, MedImmune, Gaithersburg, Maryland, United States of America.
Herren WuAntibody Discovery and Protein Engineering, MedImmune, Gaithersburg, Maryland, United States of America.
William F Dall'AcquaAntibody Discovery and Protein Engineering, MedImmune, Gaithersburg, Maryland, United States of America.
Ping TsuiAntibody Discovery and Protein Engineering, MedImmune, Gaithersburg, Maryland, United States of America.
Vaheh OganesyanAntibody Discovery and Protein Engineering, MedImmune, Gaithersburg, Maryland, United States of America.ORCID http://orcid.org/0000-0001-8910-9202
AstraZeneca (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The immunoglobulin Fc region is a homodimer consisted of two sets of CH2 and CH3 domains and has been exploited to generate two-arm protein fusions with high expression yields, simplified purification processes and extended serum half-life. However, attempts to generate one-arm fusion proteins with monomeric Fc, with one set of CH2 and CH3 domains, are often plagued with challenges such as weakened binding to FcRn or partial monomer formation. Here, we demonstrate the generation of a stable IgG4 Fc monomer with a unique combination of mutations at the CH3-CH3 interface using rational design combined with in vitro evolution methodologies. In addition to size-exclusion chromatography and analytical ultracentrifugation, we used multi-angle light scattering (MALS) to show that the engineered Fc monomer exhibits excellent monodispersity. Furthermore, crystal structure analysis (PDB ID: 5HVW) reveals monomeric properties supported by disrupted interactions at the CH3-CH3 interface. Monomeric Fc fusions with Fab or scFv achieved FcRn binding and serum half-life comparable to wildtype IgG. These results demonstrate that this monomeric IgG4 Fc is a promising therapeutic platform to extend the serum half-life of proteins in a monovalent format.

Indexed as

AnimalsChromatography, GelCrystallography, X-RayDynamic Light ScatteringEnzyme-Linked Immunosorbent AssayHalf-LifeHumansImmunoglobulin Fc FragmentsImmunoglobulin GMiceMice, TransgenicMolecular Dynamics SimulationPeptide LibraryProtein BindingProtein DomainsRecombinant ProteinsImmunoglobulin Fc FragmentsImmunoglobulin GPeptide LibraryRecombinant Proteins

Identifiers

PMID27479095
PMCPMC4968834
OpenAlexW2504215566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.